Cancer Diagnostics Market Information: By Type (Biopsy Based, Endoscopy Based, Imaging Procedure), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer), End User (Diagnostic Center, Clinic, Hospital) - Global Forecast till 2023

Market Scenario

Cancer is the uncontrolled growth of tumor cells anywhere in the body and can spread to the other parts of body. There are more than 200 different types of cancer such as breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and many more. Several methods, advance technology, have surfaced for diagnosing cancer at an early stage. The continuously rising number of patients suffering with different type of cancer is majorly leading the cancer diagnostics market.

According to the WHO, cancer was the leading cause of the total number of deaths globally as of 2015 and was responsible for 8.8 million deaths. The most common causal agents identified are cigarettes, cigars, pipes and chewing tobacco. According to a study done by Cancer Research U.K, looking at the lifestyle factors responsible, it has been found that out of 3 diagnosed cases, 1 may be linked to smoking.

According to National Instituted of Health (NIH) it has been found that as of 2016, a projected 1,685,210 new cases of cancer were reported in the United States and 595,690 individuals died from the disease which further increases the urgency and thereby the growth of the market.

Most of the cancer are hard to catch, even if we are aware of the symptoms to search for. This leads to a late diagnosis and makes the treatment more difficult. Thus, companies are more into merger and acquisition activity in order to introduce better diagnosis procedure. In this regards, Progenics Pharmaceuticals, Inc., 2015, acquired Exini Diagnostics AB in order to support its imaging and therapeutic agents with sophisticated analytical tools and other technologies to help patients and physicians understand, target and treat one of the most common cancers in the male population – prostate cancer.

Moreover, advancing technology is adding fuel to the growth of the market. Furthermore, increasing prevalence of different type of cancer drives the market growth. However, the availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors which may hamper the market growth during the forecast period.

The global cancer diagnostics market is expected to grow at a CAGR of 11.8% during the forecast period 2017-2023.

Intended Audience

- Cancer specific medical device manufacturers
- Cancer specific medical device suppliers
- Government Research Laboratory
- Private Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Medical Research Laboratories
Segmentations

The global cancer diagnostics market is segmented on the basis of types, application, and end user.
On the basis of the type, it is segmented into biopsy based, endoscopy based, imaging procedure, tumor cancer diagnostics, and others.
On the basis of the application, it is segmented into lung cancer, breast cancer, colorectal cancer, cervical cancer, prostate cancer, skin cancer, blood cancer, kidney cancer, liver cancer, pancreatic cancer, and others.
On the basis of the end user, it is segmented into diagnostic center, clinic, hospital, research institutes, and others.

Regional Analysis

The Americas dominate the global cancer diagnostics market owing to well-developed technology, increasing patient pool with cancer, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the global cancer diagnostics market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. According to Cancer research U.K, in 2014, new cases of cancer were 356,860, including 579 cases of bone cancer.

Asia Pacific is the fastest growing cancer diagnostics market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, developing countries from these region looking forward for better technology in order to improve the quality of life of their citizen.

On the other hand, in the Middle East and Africa, hold the least share of cancer diagnostics market owing to poor healthcare infrastructure.

Key Players

Some of key the players in the market are Armune BioScience, Inc. (U.S.), Arquer Diagnostics Ltd (U.K), BioMark Diagnostics Inc. (Canada), Biotheranostics, Inc. (U.S.), Cancer Diagnostics, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (Denmark), Becton, Dickinson and Company (U.S.), GE Healthcare (U.K), QIAGEN N.V. (Netherlands), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Philips Healthcare (U.K.), C.R. Bard, Inc. (U.S.).
Sources: Annual reports, Press release, White paper, and Company presentation

Contents:

1. Report Prologue
2. Market Introduction
   2.1 Definition
   2.2 Scope of the Study
      2.2.1 Research Objective
      2.2.2 Assumptions
      2.2.3 Limitations
3. Research Methodology
   3.1 Introduction
   3.2 Primary Research
   3.3 Secondary research
   3.4 Market Size Estimation
4. Market Dynamics
   4.1 Drivers
   4.2 Restraints
   4.3 Opportunities
   4.4 Challenges
   4.5 Macroeconomic Indicators
   4.6 Technology Trends & Assessment
5. Market Factor Analysis
   5.1 Porters Five Forces Analysis
      5.1.1 Bargaining Power of Suppliers
      5.1.2 Bargaining Power of Buyers
      5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

6. Global Cancer diagnostics Market, by Type
6.1 Introduction
6.2 Biopsy Based
6.2.1 Market Estimates & Forecast, 2017-2023
6.3 Endoscopy Based
6.3.1 Market Estimates & Forecast, 2017-2023
6.4 Imaging Procedure
6.4.1 Market Estimates & Forecast, 2017-2023
6.5 Tumor Cancer diagnostics
6.5.1 Market Estimates & Forecast, 2017-2023
6.6 Others
6.6.1 Market Estimates & Forecast, 2017-2023

7. Global Cancer diagnostics Market, by Application
7.1 Introduction
7.2 Lung Cancer
7.2.1 Market Estimates & Forecast, 2017-2023
7.3 Breast Cancer
7.3.1 Market Estimates & Forecast, 2017-2023
7.4 Colorectal Cancer
7.4.1 Market Estimates & Forecast, 2017-2023
7.5 Cervical Cancer
7.5.1 Market Estimates & Forecast, 2017-2023
7.6 Prostate Cancer
7.6.1 Market Estimates & Forecast, 2017-2023
7.7 Skin Cancer
7.7.1 Market Estimates & Forecast, 2017-2023
7.8 Blood Cancer
7.8.1 Market Estimates & Forecast, 2017-2023
7.9 Kidney Cancer
7.9.1 Market Estimates & Forecast, 2017-2023
7.10 Liver Cancer
7.10.1 Market Estimates & Forecast, 2017-2023
7.11 Pancreatic Cancer
7.11.1 Market Estimates & Forecast, 2017-2023
7.12 Others
7.12.1 Market Estimates & Forecast, 2017-2023

8. Global Cancer diagnostics Market, by End User
8.1 Introduction
8.2 Diagnostic Center
8.2.1 Market Estimates & Forecast, 2017-2023
8.3 Clinic
8.3.1 Market Estimates & Forecast, 2017-2023
8.4 Hospital
8.4.1 Market Estimates & Forecast, 2017-2023
8.5 Research Institutes
8.5.1 Market Estimates & Forecast, 2017-2023
8.6 Others
8.6.1 Market Estimates & Forecast, 2017-2023

9. Global Cancer diagnostics Market, by Region

9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 U.K
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

11 Company Profiles
11.1 Armune BioScience, Inc.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Arquer Diagnostics Ltd
11.2.1 Company Overview
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 QIAGEN N.V.
11.11.1 Overview
11.11.2 Product Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.12 Abbott Laboratories, Inc.
11.12.1 Overview
11.12.2 Product Overview
11.12.3 Financials
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.13 Others
12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical Industry
13 Appendix

LIST OF TABLES
Table 1 Cancer diagnostics Industry Synopsis, 2017-2023
Table 2 Global Cancer diagnostics Market Estimates and Forecast, 2017-2023, (USD Million)
Table 3 Global Cancer diagnostics Market by Region, 2017-2023, (USD Million)
Table 4 Global Cancer diagnostics Market by Type, 2017-2023, (USD Million)
Table 5 Global Cancer diagnostics Market by Application, 2017-2023, (USD Million)
Table 6 Global Cancer diagnostics Market by End Users, 2017-2023, (USD Million)
Table 7 North America Cancer diagnostics Market by Type, 2017-2023, (USD Million)
Table 8 North America Cancer diagnostics Market by Application, 2017-2023, (USD Million)
Table 9 North America Cancer diagnostics Market by End Users, 2017-2023, (USD Million)
Table 10 US Cancer diagnostics Market by Type, 2017-2023, (USD Million)
Table 11 US Cancer diagnostics Market by Application, 2017-2023, (USD Million)
Table 12 US Cancer diagnostics Market by End Users, 2017-2023, (USD Million)
Table 13 Canada Cancer diagnostics Market by Type, 2017-2023, (USD Million)
Table 14 Canada Cancer diagnostics Market by Application, 2017-2023, (USD Million)
Table 15 Canada Cancer diagnostics Market by End Users, 2017-2023, (USD Million)
Table 16 South America Cancer diagnostics Market by Type, 2017-2023, (USD Million)
Table 17 South America Cancer diagnostics Market by Application, 2017-2023, (USD Million)
Table 18 South America Cancer diagnostics Market by End Users, 2017-2023, (USD Million)
Table 19 Europe Cancer diagnostics Market by Type, 2017-2023, (USD Million)
Table 20 Europe Cancer diagnostics Market by Application, 2017-2023, (USD Million)
Table 21 Europe Cancer diagnostics Market by End Users, 2017-2023, (USD Million)
Table 22 Western Europe Cancer diagnostics Market by Type, 2017-2023, (USD Million)
Table 23 Western Europe Cancer diagnostics Market by Application, 2017-2023, (USD Million)
Table 24 Western Europe Cancer diagnostics Market by End Users, 2017-2023, (USD Million)
Table 25 Eastern Europe Cancer diagnostics Market by Type, 2017-2023, (USD Million)
Table 26 Eastern Europe Cancer diagnostics Market by Application, 2017-2023, (USD Million)
Table 27 Eastern Europe Cancer diagnostics Market by End Users, 2017-2023, (USD Million)
Table 28 Asia Pacific Cancer diagnostics Market by Type, 2017-2023, (USD Million)
Table 29 Asia Pacific Cancer diagnostics Market by Application, 2017-2023, (USD Million)
Table 30 Asia Pacific Cancer diagnostics Market by End Users, 2017-2023, (USD Million)
Table 31 Middle East & Africa Cancer diagnostics Market by Type, 2017-2023, (USD Million)
Table 32 Middle East & Africa Cancer diagnostics Market by Application, 2017-2023, (USD Million)
Table 33 Middle East & Africa Cancer diagnostics Market by End Users, 2017-2023, (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Cancer diagnostics Market
Figure 3 Segmentation Market Dynamics for Cancer diagnostics Market
Figure 4 Global Cancer diagnostics Market Share, by Type 2016
Figure 5 Global Cancer diagnostics Market Share, by Application 2016
Figure 6 Global Cancer diagnostics Market Share, by End Users, 2016
Figure 7 Global Cancer diagnostics Market Share, by Region, 2016
Figure 8 America Cancer diagnostics Market Share, by Country, 2016
Figure 9 Europe Cancer diagnostics Market Share, by Country, 2016
Figure 10 Asia Pacific Cancer diagnostics Market Share, by Country, 2016
Figure 11 Middle East & Africa Cancer diagnostics Market Share, by Country, 2016
Figure 12 Global Cancer diagnostics Market: Company Share Analysis, 2016 (%)
Figure 13 Armune BioScience, Inc.: Key Financials
Figure 14 Armune BioScience, Inc.: Segmental Revenue
Figure 15 Armune BioScience, Inc.: Geographical Revenue
Figure 16 Arquer Diagnostics Ltd: Key Financials
Figure 17 Arquer Diagnostics Ltd: Segmental Revenue
Figure 18 Arquer Diagnostics Ltd: Geographical Revenue
Figure 19 BioMark Diagnostics Inc.: Key Financials
Figure 20 BioMark Diagnostics Inc.: Segmental Revenue
Figure 21 BioMark Diagnostics Inc.: Geographical Revenue
Figure 22 Biotheranostics, Inc.: Key Financials
Figure 23 Biotheranostics, Inc.: Segmental Revenue
Figure 24 Biotheranostics, Inc.: Geographical Revenue
Figure 25 Cancer Diagnostics, Inc.: Key Financials
Figure 26 Cancer Diagnostics, Inc.: Segmental Revenue
Figure 27 Cancer Diagnostics, Inc.: Geographical Revenue
Figure 28 Agilent Technologies, Inc.: Key Financials
Figure 29 Agilent Technologies, Inc.: Segmental Revenue
Figure 30 Agilent Technologies, Inc.: Geographical Revenue
Figure 31 Thermo Fisher Scientific, Inc.: Key Financials
Figure 32 Thermo Fisher Scientific, Inc.: Segmental Revenue
Figure 33 Thermo Fisher Scientific, Inc.: Geographical Revenue
Figure 34 Illumina, Inc.: Key Financials
Figure 35 Illumina, Inc.: Segmental Revenue
Figure 36 Illumina, Inc.: Geographical Revenue
Figure 37 Becton, Dickinson and Company: Key Financials
Figure 38 Becton, Dickinson and Company: Segmental Revenue
Figure 39 Becton, Dickinson and Company: Geographical Revenue
Figure 40 GE Healthcare: Key Financials
Figure 41 GE Healthcare: Segmental Revenue
Figure 42 GE Healthcare: Geographical Revenue
Figure 43 QIAGEN N.V.: Key Financials
Figure 44 QIAGEN N.V.: Segmental Revenue
Figure 45 QIAGEN N.V.: Geographical Revenue
Figure 46 Abbott Laboratories, Inc.: Key Financials
Figure 47 Abbott Laboratories, Inc.: Segmental Revenue
Figure 48 Abbott Laboratories, Inc.: Geographical Revenue